Remedium Lifecare Limited (BOM:539561)
India
· Delayed Price · Currency is INR 1.820
+0.030 (1.68%)
At close: Apr 28, 2025
Remedium Lifecare Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2015 - 2019 |
| Operating Revenue | 15,494 | 40,417 | 5,098 | 5,048 | 900.34 | 28.9 | Upgrade
|
| Other Revenue | - | - | - | - | 0.02 | - | Upgrade
|
| Revenue | 15,494 | 40,417 | 5,098 | 5,048 | 900.36 | 28.9 | Upgrade
|
| Revenue Growth (YoY) | -43.15% | 692.75% | 1.00% | 460.66% | 3015.21% | 1716.59% | Upgrade
|
| Cost of Revenue | 15,771 | 40,014 | 4,939 | 4,985 | 877.51 | 17.08 | Upgrade
|
| Gross Profit | -276.7 | 403.24 | 159.69 | 63.09 | 22.85 | 11.82 | Upgrade
|
| Selling, General & Admin | 21.5 | 21.46 | 16.24 | 11.14 | 6.07 | 5.18 | Upgrade
|
| Other Operating Expenses | 56.91 | 47.24 | 76.29 | 34.19 | 9.57 | 2.77 | Upgrade
|
| Operating Expenses | 78.84 | 69.27 | 94.04 | 46.07 | 16.24 | 8.08 | Upgrade
|
| Operating Income | -355.54 | 333.97 | 65.65 | 17.02 | 6.62 | 3.74 | Upgrade
|
| Interest Expense | -76.93 | -40.24 | -0.72 | -0.7 | -0.11 | -0.07 | Upgrade
|
| Interest & Investment Income | 0.94 | 0.94 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 209.87 | 209.87 | 8.27 | - | 0.03 | 0.09 | Upgrade
|
| Other Non Operating Income (Expenses) | -80.45 | 0 | 0.76 | -1.07 | - | -0 | Upgrade
|
| EBT Excluding Unusual Items | -302.11 | 504.54 | 73.96 | 15.25 | 6.53 | 3.75 | Upgrade
|
| Pretax Income | -302.11 | 504.54 | 73.96 | 15.25 | 6.53 | 3.75 | Upgrade
|
| Income Tax Expense | -95.27 | 177.24 | 19.7 | 4.47 | 1.72 | 0.98 | Upgrade
|
| Net Income | -206.84 | 327.3 | 54.26 | 10.78 | 4.81 | 2.77 | Upgrade
|
| Net Income to Common | -206.84 | 327.3 | 54.26 | 10.78 | 4.81 | 2.77 | Upgrade
|
| Net Income Growth | - | 503.20% | 403.44% | 124.31% | 73.47% | 3362.50% | Upgrade
|
| Shares Outstanding (Basic) | 515 | 403 | 403 | 403 | 403 | 403 | Upgrade
|
| Shares Outstanding (Diluted) | 515 | 403 | 403 | 404 | 404 | 403 | Upgrade
|
| Shares Change (YoY) | 70.39% | - | -0.12% | -0.03% | 0.14% | - | Upgrade
|
| EPS (Basic) | -0.40 | 0.81 | 0.13 | 0.03 | 0.01 | 0.01 | Upgrade
|
| EPS (Diluted) | -0.40 | 0.81 | 0.13 | 0.03 | 0.01 | 0.01 | Upgrade
|
| EPS Growth | - | 503.20% | 404.03% | 124.37% | 73.22% | 3369.70% | Upgrade
|
| Free Cash Flow | - | -741.61 | 204.57 | 112.33 | -102.51 | -4.42 | Upgrade
|
| Free Cash Flow Per Share | - | -1.84 | 0.51 | 0.28 | -0.25 | -0.01 | Upgrade
|
| Gross Margin | -1.79% | 1.00% | 3.13% | 1.25% | 2.54% | 40.89% | Upgrade
|
| Operating Margin | -2.30% | 0.83% | 1.29% | 0.34% | 0.73% | 12.92% | Upgrade
|
| Profit Margin | -1.33% | 0.81% | 1.06% | 0.21% | 0.53% | 9.58% | Upgrade
|
| Free Cash Flow Margin | - | -1.84% | 4.01% | 2.23% | -11.39% | -15.28% | Upgrade
|
| EBITDA | -355.68 | 334.54 | 67.16 | 17.76 | 7.22 | 3.87 | Upgrade
|
| EBITDA Margin | -2.30% | 0.83% | 1.32% | 0.35% | 0.80% | 13.38% | Upgrade
|
| D&A For EBITDA | -0.14 | 0.57 | 1.51 | 0.74 | 0.6 | 0.13 | Upgrade
|
| EBIT | -355.54 | 333.97 | 65.65 | 17.02 | 6.62 | 3.74 | Upgrade
|
| EBIT Margin | -2.30% | 0.83% | 1.29% | 0.34% | 0.73% | 12.92% | Upgrade
|
| Effective Tax Rate | - | 35.13% | 26.63% | 29.33% | 26.39% | 26.11% | Upgrade
|
| Revenue as Reported | 15,625 | 40,628 | 5,098 | 5,048 | 900.36 | 28.9 | Upgrade
|
| Advertising Expenses | - | 3.03 | 0.31 | 2.36 | 0.43 | 1.57 | Upgrade
|
Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.